|
Recommendation category
|
Number of audits
|
Implemented recommendations
|
Implementation rate (%)
|
|---|
|
All
|
313
|
234
|
75
|
|
Discontinue all agent(s)
|
115
|
85
|
74
|
|
De-escalatea
|
65
|
53
|
82
|
|
Limit durationb
|
21
|
13
|
62
|
|
Consult infectious diseases
|
19
|
16
|
84
|
|
Optimize dose
|
14
|
7
|
50
|
|
Broaden c
|
5
|
3
|
60
|
|
Convert parenteral to orald
|
3
|
3
|
100
|
|
More than 1 category
|
71
|
54
|
76
|
- NOTE:
- a - Discontinuation of one or more agent(s) and/or substitution of alternate agent(s) with decreased spectrum of activity.
- b - Limit duration for same agent(s) at same dose, route and schedule.
- c - Addition of one or more agent(s) and/or substitution of alternate agent(s) with increased spectrum of activity.
- d - Parenteral to oral conversion(s) of same agent(s) at same dose and schedule.
